Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease
Topic / Pathology
- Parkinson's Disease
Sponsor
Lille Hospital
Investigator
Pr David Devos
Scientific publication(s)
-
Devos D et al; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055.
-
Moreau C et al. Iron as a therapeutic target for Parkinson's disease. Mov Disord. 2018 Apr;33(4):568-574.
-
Devos D et al. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 2020 Feb;127(2):189-203.
Status
Published results
